Cargando…
Ziritaxestat Drug–Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition
In vitro signals indicate that ziritaxestat is a weak cytochrome P450 (CYP) 3A4 inhibitor and inducer. Therefore, potential drug–drug interactions (DDIs) with oral contraceptives were examined at a time when ziritaxestat was under development for treatment of fibrotic diseases. This open‐label, cros...
Autores principales: | Helmer, Eric, Karimian, Negin, Van Assche, Karen, Seghers, Ineke, Le Tallec, Sandrine, Cherala, Ganesh, Scott, Graham, Namour, Florence S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540497/ https://www.ncbi.nlm.nih.gov/pubmed/35713964 http://dx.doi.org/10.1002/cpt.2689 |
Ejemplares similares
-
Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model
por: Perrier, Jeremy, et al.
Publicado: (2023) -
Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration
por: Helmer, Eric, et al.
Publicado: (2021) -
Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1
por: Edavana, Vineetha Koroth, et al.
Publicado: (2011) -
Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug–Drug Interaction Studies?
por: Dauki, Anees M., et al.
Publicado: (2022) -
Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women
por: Atrio, Jessica, et al.
Publicado: (2014)